The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended AstraZeneca's Tagrisso ...

The CHMP's opinion is based on late-stage data, which show that treatment with AZN's Tagrisso extends progression-free ...

Panelist discusses how the second interim overall survival data from MARIPOSA-2, presented at the European Society for ...

Get detailed information on Osimertinib, including pronunciation, uses, dosage guidelines, indications, and instructions on how and when to take it and when to avoid it. The updated prescription ...

European Union recommends approval of AstraZeneca’s Tagrisso for patients with unresectable EGFR-mutated lung cancer ...

In a move aimed at providing relief to cancer patients, the National Pharmaceutical Pricing Authority (NPPA) has directed ...

You should read both the consultation document and the accompanying evidence (see the committee papers) before making any comments. You must make your comments ...

Researchers used base and prime editing to uncover new EGFR gene mutations that affect cancer progression and drug resistance ...

ENRICHED CTCS AND CTDNA PROVIDES COMPLEMENTARY INFORMATION IN NSCLC PATIENTS TREATED WITH ASTRAZENECA'S OSIMERTINIB. The additi ...

So it's a very good option if a patient progresses on osimertinib. We don't have a specific genetic escape pathway that we can identify. This is really the standard of care with particular ...